Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 7-8/2016

01.04.2016 | case report

Moclobemide as add-on therapy to agomelatine in a patient with treatment-resistant major depressive disorder: a psychopharmacological case

verfasst von: Pharm D, PhD Matej Stuhec, MD, PhD Robert Oravecz

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 7-8/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Objective

Treatment-resistant depression is a major depressive disorder that does not respond to adequate treatment of at least two antidepressants and is one of the major clinical challenges for clinicians and clinical pharmacists. One treatment option is to switch the patient to a different medication. Another option is to add a medication to the patient’s current pharmacotherapy. This article presents an improvement of symptoms induced by a combination of moclobemide (MOC) and agomelatine (AG) treatment in a 48-year-old Caucasian woman with treatment-resistant major depressive disorder (MDD). The patient had been treated with numerous antidepressants in the last 2 years that had not been effective or had caused serious adverse effects. When MOC 300 mg daily was added to AG 25 mg daily, the patient recovered progressively without any adverse effects. Her functional status also appeared stable. No other drugs known to interact with AG were administered. The MOC dose was subsequently increased to 600 mg daily and was taken with AG 25 mg daily and zolpidem 5 mg daily.

Discussion

The positive effects of AG or MOC on MDD have been widely reported, but there have not been reports of a combined treatment with MOG and AG improving symptoms of treatment-resistant MDD. The exact mechanism of this effect on the central nervous system is unknown. The additive activity could have been caused by a broader spectrum activity of AG and MOC.

Conclusion

In this report, we identified a case with positive evidence of this antidepressant combination relieving the symptoms of treatment-resistant MDD, which is otherwise difficult to manage. This case report may serve to help clinicians and clinical pharmacists as a new treatment option for treatment-resistant MDD, although further research is needed to confirm this practice.
Literatur
1.
Zurück zum Zitat Fulton B, Benfield P. Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs. 1996;52:450–74. CrossRefPubMed Fulton B, Benfield P. Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs. 1996;52:450–74. CrossRefPubMed
2.
Zurück zum Zitat Angst J, Amrein R, Stabl M. Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies. J Clin Psychopharmacol. 1995;15:16S–23S. CrossRefPubMed Angst J, Amrein R, Stabl M. Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies. J Clin Psychopharmacol. 1995;15:16S–23S. CrossRefPubMed
3.
Zurück zum Zitat Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20:226–47. CrossRefPubMed Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20:226–47. CrossRefPubMed
4.
Zurück zum Zitat Kennedy SH. Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors. J Psychiatry Neurosci. 1997;22:127–31. PubMedPubMedCentral Kennedy SH. Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors. J Psychiatry Neurosci. 1997;22:127–31. PubMedPubMedCentral
5.
Zurück zum Zitat Rimón R, Jääskeläinen J, Kaartinen P, et al. Moclobemide versus imipramine in depressed out-patients: a double-blind multi-centre study. Int Clin Psychopharmacol. 1993;7:141–7. CrossRefPubMed Rimón R, Jääskeläinen J, Kaartinen P, et al. Moclobemide versus imipramine in depressed out-patients: a double-blind multi-centre study. Int Clin Psychopharmacol. 1993;7:141–7. CrossRefPubMed
6.
Zurück zum Zitat Owen RT. Agomelatine: a novel pharmacological approach to treating depression. Drugs Today. 2009;45:599–608. CrossRefPubMed Owen RT. Agomelatine: a novel pharmacological approach to treating depression. Drugs Today. 2009;45:599–608. CrossRefPubMed
7.
8.
9.
Zurück zum Zitat Fekadu A, Wooderson SC, Markopoulo K, et al. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord. 2009;116:4–11. CrossRefPubMed Fekadu A, Wooderson SC, Markopoulo K, et al. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord. 2009;116:4–11. CrossRefPubMed
10.
Zurück zum Zitat Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996;31:444–69. CrossRefPubMed Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996;31:444–69. CrossRefPubMed
11.
Zurück zum Zitat Štuhec M. Excessive sweating induced by interaction between agomelatine and duloxetine hydrochloride: case report and review of the literature. Wien Klin Wochenschr. 2015. [Epub ahead of print]. Štuhec M. Excessive sweating induced by interaction between agomelatine and duloxetine hydrochloride: case report and review of the literature. Wien Klin Wochenschr. 2015. [Epub ahead of print].
12.
Zurück zum Zitat Thomas SJ, Shin M, McInnis MG, et al. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression. Pharmacotherapy. 2015;35:433–49. CrossRefPubMed Thomas SJ, Shin M, McInnis MG, et al. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression. Pharmacotherapy. 2015;35:433–49. CrossRefPubMed
13.
Zurück zum Zitat Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45. CrossRefPubMed Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45. CrossRefPubMed
14.
Zurück zum Zitat Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf. 2011;34:709–31. CrossRefPubMed Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf. 2011;34:709–31. CrossRefPubMed
15.
Zurück zum Zitat Gram LF, Guentert TW, Grange S, et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther. 1995;57:670–7. CrossRefPubMed Gram LF, Guentert TW, Grange S, et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther. 1995;57:670–7. CrossRefPubMed
16.
Zurück zum Zitat Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29:259–66. CrossRefPubMed Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29:259–66. CrossRefPubMed
17.
Zurück zum Zitat Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28:561–6. CrossRefPubMed Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28:561–6. CrossRefPubMed
Metadaten
Titel
Moclobemide as add-on therapy to agomelatine in a patient with treatment-resistant major depressive disorder: a psychopharmacological case
verfasst von
Pharm D, PhD Matej Stuhec
MD, PhD Robert Oravecz
Publikationsdatum
01.04.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 7-8/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0861-0

Weitere Artikel der Ausgabe 7-8/2016

Wiener klinische Wochenschrift 7-8/2016 Zur Ausgabe